Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Investigators Discover Compounds that Block Reactivation of Latent HIV-1

By American Society for Microbiology | December 4, 2018

A team of investigators from the University of Pittsburgh has identified compounds that block the reactivation of latent HIV-1 in a human cell line containing the latent virus. The research is published December 3rd in Antimicrobial Agents and Chemotherapy, a journal of the American Society for Microbiology.

The compounds the researchers tested came from a library of 418 different “kinase inhibitors.” Kinases target a wide range of signaling pathways within cells, regulating critical cellular functions such as DNA transcription and translation, and cellular metabolism. These pathways apparently include ones that can reverse latency of HIV-1 virus that has become integrated into the human genome. Thus, the research could lead to ways to permanently suppress HIV infections, said Benni E. Vargas, a Ph.D. student in Microbiology and Immunology at the University of Pittsburgh School of Medicine

The researchers had infected the cell line with HIV-1 that then became dormant within the cells. The virus contained a “reporter gene,” which would light up during reactivation so that the investigators would know if reactivation occurred. The cell cultures were then given an HIV-1 activating small molecule compound, and each culture was exposed to one of the 418 different kinase inhibitors.

“There’s a need to understand the mechanisms and signaling pathways by which the host cell regulates HIV-1 latency and reactivation,” said Vargas. “What better way to identify these host signaling pathways than to screen a whole library of drugs that target different parts of the host signaling pathway?”

A potential downside of the kinase inhibitors is possible toxicity to human cells, said Mr. Vargas. The investigators gauged toxicity by measuring cellular production of ATP, a compound manufactured in cells which functions as cellular fuel, within the tiny cellular motors, the mitochondria. A notable reduction in the quantity of ATP, as present, as compared to normal, would indicate toxicity, said Mr. Vargas. Twelve kinase inhibitors blocked reactivation irrespective of latency reversing agent, and two of these did so with minimal toxicity.

The motivation for the research was that several other groups had previously identified inhibitors of kinases that block reactivation of the dormant HIV-1 provirus, said Vargas.


Filed Under: Infectious Disease

 

Related Articles Read More >

Secretary of Health removes all current members of the CDC advisory committee on immunization practices
covid-19 vaccine
FDA COVID booster pullback jolts vaccine stocks before gains cool
Coronavirus Covid-19 background - 3d rendering
Pregnancy associated with less long COVID: Researchers call for studies on protective biology
How technology advances are helping scientists unlock the mysteries of zoonotic diseases
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE